Ertapenem: a review of its use in the treatment of bacterial infections (Q36286220)

13 August 2017

1 reference

title

Ertapenem: a review of its use in the treatment of bacterial infections (English)

1 reference

13 August 2017

2

Caroline M Perry

1 reference

13 August 2017

1

Gillian M Keating

1 reference

13 August 2017

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

65

1 reference

13 August 2017

15

1 reference

13 August 2017

2151-2178

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200565150-00013

13 August 2017

0 references

cites work

Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians

1 reference

12 December 2020

Predominance and genetic diversity of community- and hospital-acquired CTX-M extended-spectrum beta-lactamases in York, UK.

1 reference

12 December 2020

Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

1 reference

12 December 2020

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

1 reference

12 December 2020

Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000).

1 reference

12 December 2020

Properties and potential of ertapenem

1 reference

12 December 2020

In vitro activity of ertapenem against selected respiratory pathogens

1 reference

12 December 2020

Emerging epidemic of metallo-beta-lactamase-mediated resistances.

1 reference

12 December 2020

Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

1 reference

12 December 2020

Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone

1 reference

12 December 2020

Ertapenem: a review of its use in the management of bacterial infections

1 reference

12 December 2020

Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients

1 reference

12 December 2020

Activities of doripenem (S-4661) against drug-resistant clinical pathogens

1 reference

12 December 2020

In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics

1 reference

12 December 2020

Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens

1 reference

12 December 2020

In vitro antimicrobial activity of doripenem, a new carbapenem

1 reference

12 December 2020

Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection

1 reference

12 December 2020

Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects

1 reference

12 December 2020

In vitro activity of antimicrobial agents against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.

1 reference

12 December 2020

Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis

1 reference

12 December 2020

Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents

1 reference

12 December 2020

Pharmacokinetics of intramuscularly administered ertapenem

1 reference

12 December 2020

Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model

1 reference

12 December 2020

A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults

1 reference

12 December 2020

Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000.

1 reference

12 December 2020

Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study

1 reference

12 December 2020

Advances in the treatment of diabetic foot infections

1 reference

12 December 2020

Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy

1 reference

12 December 2020

Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam

1 reference

12 December 2020

In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates

1 reference

12 December 2020

Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections

1 reference

12 December 2020

Complicated infections of skin and skin structures: when the infection is more than skin deep

1 reference

12 December 2020

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

1 reference

12 December 2020

The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary

1 reference

12 December 2020

In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains

1 reference

12 December 2020

Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia

1 reference

12 December 2020

General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam

1 reference

12 December 2020

Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam

1 reference

12 December 2020

Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study

1 reference

12 December 2020

Pharmacokinetics of ertapenem in healthy young volunteers.

1 reference

12 December 2020

Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.

1 reference

12 December 2020

In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers

1 reference

12 December 2020

Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.

1 reference

12 December 2020

Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme

1 reference

12 December 2020

Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.

1 reference

12 December 2020

In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds

1 reference

12 December 2020

Recent developments in carbapenems

1 reference

12 December 2020

Ertapenem, the first of a new group of carbapenems

1 reference

12 December 2020

Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

1 reference

12 December 2020

A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia

1 reference

12 December 2020

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

1 reference

12 December 2020

Diagnosis and treatment of diabetic foot infections

1 reference

12 December 2020

Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems

1 reference

12 December 2020

Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases

1 reference

12 December 2020

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).

1 reference

12 December 2020

Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy

1 reference

12 December 2020

Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae

1 reference

12 December 2020

Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity

1 reference

12 December 2020

Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections

1 reference

12 December 2020

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

1 reference

12 December 2020

The new beta-lactamases.

1 reference

12 December 2020

Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections

1 reference

12 December 2020

In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains

1 reference

12 December 2020

Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.

1 reference

12 December 2020

Emerging carbapenemases in Gram-negative aerobes

1 reference

12 December 2020

Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents

1 reference

12 December 2020

Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections

1 reference

12 December 2020

In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria

1 reference

12 December 2020

Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.

1 reference

12 December 2020

Comparative pharmacokinetics of the carbapenems: clinical implications

1 reference

12 December 2020

Ertapenem therapy for community-acquired pneumonia in the elderly

1 reference

12 December 2020

Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults

1 reference

12 December 2020

Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers

1 reference

12 December 2020

Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.

1 reference

12 December 2020

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City

1 reference

12 December 2020

Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers

1 reference

12 December 2020

Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections

1 reference

12 December 2020

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms

1 reference

12 December 2020

Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy

1 reference

12 December 2020

Ertapenem versus Piperacillin-Tazobactam for Treatment of Mixed Anaerobic Complicated Intra-Abdominal, Complicated Skin and Skin Structure, and Acute Pelvic Infections

1 reference

12 December 2020

Extended-spectrum beta-lactamase-producing Enterobacteriaceae at Middlemore Hospital

1 reference

12 December 2020

In vitro activity of ertapenem: review of recent studies

1 reference

12 December 2020

CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa

1 reference

12 December 2020

In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

1 reference

12 December 2020

Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model

1 reference

12 December 2020

Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data

1 reference

12 December 2020

Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.

1 reference

12 December 2020

A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults

1 reference

12 December 2020

Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections

1 reference

12 December 2020

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections

1 reference

12 December 2020

Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies

1 reference

12 December 2020

In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.

1 reference

12 December 2020

In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials

1 reference

12 December 2020

Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain

1 reference

12 December 2020

Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes

1 reference

12 December 2020

Effect of ertapenem protein binding on killing of bacteria

1 reference

12 December 2020

Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases

1 reference

12 December 2020

In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria

1 reference

12 December 2020

10.2165/00003495-200565150-00013

Identifiers

DOI

1 reference

PubMed ID

16225376

Dimensions Publication ID

13 August 2017

0 references

1 reference

PubMed ID

16225376